Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
A phase 1/2 trial of Pembrolizumab in melanoma and metastatic cancer, run by CJ Bioscience, Inc., now recruiting.
Overview
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05877430 by CJ Bioscience, Inc., with 160 participants planned, started 2023-09-11 and due to reach its primary completion in 2026-07. Interventions recorded: CJRB-101, Pembrolizumab injection. Conditions listed: NSCLC, HNSCC, Melanoma, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Setting
Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Phase
Phase 1/2
Sponsor
CJ Bioscience, Inc.
Registry
Enrolled
160